1-4 of 4
Jeanette Wood, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pharmacodynamic (PD) Biomarker Assay Validation for SB1518, a Novel Oral JAK2 Inhibitor in Phase 1 Clinical Trials for Advanced Leukemias, Myeloproliferative Diseases and Lymphoma.

Stefan Hart, Ph.D., Kee Chuan Goh, Ph.D., Yong Cheng Tan, M.Sc., Amalini Chithra, B.Sc., Jeanette Wood, PhD
Journal: Blood
Blood (2009) 114 (22): 1888.
https://doi.org/10.1182/blood.V114.22.1888.1888
Published: 2009
Journal Articles

Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis.

Srdan Verstovsek, MD, PhD, Olatoyosi Odenike, MD, Bart Scott, MD, Zeev Estrov, MD, Jorge Cortes, MD, Deborah A. Thomas, MD, Jeanette Wood, PhD, Kantharaj Ethirajulu, PhD, Ann Lowe, MD, Huan J. Zhu, MD, PhD, Hagop Kantarjian, MD, H. Joachim Deeg, MD
Journal: Blood
Blood (2009) 114 (22): 3905.
https://doi.org/10.1182/blood.V114.22.3905.3905
Published: 2009
Journal Articles

Phase-I Study of the Novel Oral JAK-2 Inhibitor SB1518 in Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity.

Anas Younes, MD, Michelle Fanale, M.D., Peter McLaughlin, Amanda R Copeland, MS, Silvana de Castro Faria, Jeanette Wood, PhD, Kantharaj Ethirajulu, PhD, Huan J. Zhu, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 588.
https://doi.org/10.1182/blood.V114.22.588.588
Published: 2009
Journal Articles

The Effects of SB1518, a Novel Oral JAK2 Inhibitor, On Ex Vivo Expanded PV Erythroid Progenitors Correlate with Clinical Observations.

Kee Chuan Goh, Ph.D., Stefan Hart, Ph.D., Yong Cheng Tan, M.Sc., Amalini Chithra, B.Sc., Kiat H. Ong, MBBS, MRCP, FRCPA, Jeanette Wood, PhD
Journal: Blood
Blood (2009) 114 (22): 2913.
https://doi.org/10.1182/blood.V114.22.2913.2913
Published: 2009